Should practitioners administer these drugs to patients with advanced liver disease, despite the risks?
Blood-Borne Diseases
Latest News
Advertisement
Advertisement
Did you read this week’s top infectious disease news coverage from Contagion®?
It is becoming increasingly clear that the hepatitis C virus (HCV) can wreak havoc on a patient’s psychological well-being, even in the absence of a continued viral presence.
Elimination of viral hepatitis depends on individuals actively participating in their own healthcare and management. They can only do this if they understand why and how to protect their miraculous, life-sustaining liver from harm. Education is the key to prevention.
Members of Doctors Without Borders/Medecins Sans Frontieres discussed the aftermath of the 2014-2015 epidemic in a recent webcast.
The US Food and Drug Administration just announced that it is allowing the marketing of a new test kit for bloodstream infections.
The Centers for Disease Control and Prevention recently published a study detailing a case of Ebola virus RNA persistence in the semen of a male Ebola survivor with HIV.
A new study reports that a substantial proportion of secondary cases in the 2014 to 2015 Ebola epidemic descended from a small number of superspreaders.
Researchers presented their findings on pre-seroconversion window in patients with acute HCV infection at the Conference on Retrovirus and Opportunistic Infections in Seattle, Washington.
Researchers found that HCV infection may be linked to more cancers besides hepatocellular carcinoma, as well as certain types of non-Hodgkin lymphoma.
In a recent CHeCS study, investigators sought to identify the prevalence of cirrhosis, decompensated cirrhosis, and death, among 11,169 adults with HCV in the United States between 2006 and 2014.
A retrospective study found hepatitis C reinfection rates high are in HIV-positive men who have sex with men from four western European countries.
Here are the changes that have been made to the 2017 immunization schedules, as reported in the CDC’s most recent MMWR.
Regulus Therapeutic’s hepatitis C drug, RG-101, has been on clinical hold since mid-2016; FDA calls for additional data before hold is lifted.
The retrospective study included a cohort of patients from six countries across Europe who were diagnosed with HCV and received daclatasvir during the Named Patient Program.
The European Medicines Agency has fully validated Gilead’s SOf/VEL/VOX regimen to treat hepatitis C (HCV).
Researchers have found that those with type 2 diabetes have a higher prevalence of chronic hepatitis B virus infection than those with adult onset-autoimmune diabetes and those who do not have diabetes at all.
Quest Diagnostics has just launched a new hepatitis B virus quantitative test that will allow physicians to more effectively monitor patient response to antiviral drugs and tailor treatment regimens.
Insurance companies are denying members coverage to expensive drugs, like Harvoni, and those infected with HCV are filing lawsuits.
A new project aims to develop and assess new hepatitis C vaccination strategies in an effort to improve treatment.
New research from the Medical University of Vienna has made a connect between blood infections and an increased risk of arteriosclerosis.
Researchers have found that multidrug-resistant Candida auris, though capable of forming a biofilm that aids in its spread throughout hospitals, is susceptible to chlorhexidine.
In a phase 3 clinical trial, Japanese patients with chronic hepatitis C (HCV) infection without liver cirrhosis were able to achieve high sustained viral response rates after taking an investigational HCV drug from AbbVie.
Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention, explains why it’s important for individuals to know that they are infected with hepatitis C, although they may be asymptomatic.
These findings discredit previous allegations that this outbreak was the cause of one source and that the number of cases is higher than that identified in previous years.
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
2
Fungal-WHAT? Updates to the WHO Antifungal Pipeline
3
From Pathogen to Infectious Disease Diagnosis: Reflex Testing Targets Hepatitis D Gap
4
FDA Tentatively Approves First Generic Lenacapavir PrEP for 120 LMICs
5